ContractClinical Trial Agreement • June 5th, 2014
Contract Type FiledJune 5th, 2014CLINICAL TRIAL AGREEMENT FOR PROTOCOL GS-US-352-1214 CONTRATTO DI SPERIMENTAZIONE CLINICA PER IL PROTOCOLLO GS-US- 352-1214 This Clinical Trial Agreement (“Agreement”) is entered into as of the date of the last signature hereto (the “Effective Date”) by and between Azienda U.L.S.S. n.6 “Vicenza” Ospedale San Bortolo, with an address at viale Rodolfi, 37 – 36100 Vicenza – Italy (the “Institution”) and Gilead Sciences, Inc., a Delaware corporation with headquarters located at 333 Lakeside Drive, Foster City, California, 94404, U.S.A. (together with its affiliates and subsidiaries, “Gilead”), in connection with a clinical trial conducted pursuant to Protocol GS-US-352-1214, “A Phase 3, Randomized Study To Evaluate the Efficacy of Momelotinib Versus Best Available Therapy in Anemic or Thrombocytopenic Subjects with Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis who were Treated with Ruxolitinib” (together with any amendments th